hero image

CORRECTING and REPLACING Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference

November 10, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--First graph, first sentence of release dated November 9, 2009, should read: ...Friday, November 13, 2009 at 8:30 a.m. MST, 10:30 a.m. EST. (sted ...Friday, November 13, 2009 at 8:30 a.m. MST, 6:30 a.m. EST.).

The corrected release reads:

BIOGEN IDEC TO PRESENT AT THE 2009 ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE

Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation at the 2009 Annual Credit Suisse Healthcare Conference will be webcast live via the internet, on Friday, November 13, 2009 at 8:30 a.m. MST, 10:30 a.m. EST. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

 

Biogen Idec
Karen Jewell, 617-679-2757
Investor Relations

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.